Genmab partner gets approval for lung cancer drug from Duobody platform

Janssen Pharmaceuticals has received approval for lung cancer drug Rybrevant

Photo: Joost Melis / Genmab / PR

On Friday, Genmab's partner Janssen Pharmaceuticals has been granted approval to launch lung cancer drug Rybrevant from the US Food and Drug Administration (FDA).

The drug was developed via Genmab's Duobody platform making it the first product from this platform to receive regulatory approval.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs